Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2

Zhenming Jin a, b, 4, Haofeng Wang a, c, d, Yinkai Duan a, d, Haitao Yang a, **

** Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
a School of Life Sciences and School of Medicine, Tsinghua University, Beijing, China
b School of Life Sciences, Tianjin University, Tianjin, China

corresponding author. Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China

ARTICLE INFO
Article history:
Received 18 October 2020
Accepted 20 October 2020
Available online 21 November 2020

Keywords:
Main protease
RNA-dependent RNA polymerase
SARS-CoV-2
Inhibitors

ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented global health crisis. It is particularly urgent to develop clinically effective therapies to contain the pandemic. The main protease (Mpro) and the RNA-dependent RNA polymerase (RdRP), which are responsible for the viral polyprotein proteolytic process and viral genome replication and transcription, respectively, are two attractive drug targets for SARS-CoV-2. This review summarizes up-to-date progress in the structural and pharmacological aspects of those two key targets above. Different classes of inhibitors individually targeting Mpro and RdRP are discussed, which could promote drug development to treat SARS-CoV-2 infection.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction
Coronaviruses (CoVs) are enveloped, single-stranded positive-sense RNA (+ssRNA) viruses that feature a crown-like appearance under an electron microscope. CoVs belong to the subfamily Orthocoronavirinae, family Coronaviridae and the order Nidovirales. Members of the subfamily are classified into four genera according to their genome sequences and serological reactions: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. Among them, Alphacoronavirus is further divided into subgroups 1a-1b, and Betacoronavirus is divided into subgroups 2a-2d [1].

CoVs infect numerous species of vertebrates and can also be classified into animal and human CoVs according to their hosts. They are ecologically diverse, with enormous variation among bats, indicating that bats can serve as natural reservoirs for many CoVs [2-4]. Many diseases of domestic animals are associated with animal CoVs, such as porcine epidemic diarrhea virus (PEDV) [5], feline infectious peritonitis virus (FIPV) [6] and porcine deltacoronavirus (PDCoV) [7].

Some members of Alphacoronavirus and Betacoronavirus can infect humans and cause respiratory syndromes. Human coronaviruses (HCoVs) include 229 E (HCoV-229 E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), and HKU1 (HCoV-HKU1), which are responsible for 10%-30% of upper respiratory tract infections in adults, characterized by a symptom of mild respiratory illness like common cold [8,9]. In the past two decades, there have been two severe respiratory syndrome epidemics caused by the transmission of an animal Betacoronavirus to humans [2]. In November 2002, the severe acute respiratory syndrome (SARS) first emerged in Guangdong Province, China [10], causing worldwide concern as it spread via international travel and trade to over 20 countries. Ultimately, measures of infection control rather than medical interventions contained the SARS pandemic. By July 2003, the SARS-CoV had resulted in 8096 reported cases and 774 deaths (mortality rate of approximately 10%) [11]. In June 2012, a decade after the emergence of SARS, another highly contagious CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), was isolated from the sputum of a Saudi man who died from acute pneumonia and renal failure [12]. As of November 2019, there were 2494 confirmed cases of MERS and 858 deaths (mortality rate of approximately 35%) according to the World Health Organization (WHO), the majority of which were reported from Saudi Arabia [13].

In December 2019, the first clustered cases of a severe pneumonia were reported, and most of the patients are reported to having exposed to a large seafood market [14-17]. On January 7th, the
causative pathogen was isolated and identified as a novel member of Betacoronavirus that shares ~96% sequence identity with bat RaTG13 CoV and ~80% identity with SARS-CoV [16]. This virus was initially named 2019 novel coronavirus (2019-nCoV) and later renamed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) according to its taxonomic and phylogenetic similarities with SARS-CoV [18]. Symptoms associated with COVID-19 include fever, cough, fatigue, nausea, and shortness of breath. The severity of the symptoms can range from mild to fatal, which poses a higher risk for older adults or people with medical conditions [19,20]. The WHO designated COVID-19 the name of this epidemic disease and subsequently declared it a pandemic. To date, there have been over 30 million confirmed COVID-19 cases and over 1 million related deaths worldwide across more than 180 countries [21]. The mortality rate of COVID-19 is estimated to be approximately 3%, which is lower than that of SARS and MERS. Although the remaining undetected and asymptomatic infections may affect the precise value [22], the basic reproduction number ($R_0$) value of COVID-19 is estimated between 2–3 [23], which means it is highly contagious.

Unfortunately, no approved effective vaccines or specific antiviral drugs are currently available to prevent and treat COVID-19. Due to a stark warning over the spread of COVID-19, it is urgently required to identify and characterize drug targets for SARS-CoV-2 and to develop vaccines and effective drugs.

In this review, recent advances in structural and pharmacological studies of the SARS-CoV-2 main protease (M\textsuperscript{pro}) and RNA-dependent RNA polymerase (RdRP) will be summarized and discussed.

2. Structure and function of SARS-CoV-2 M\textsuperscript{pro}

2.1. Overview of SARS-CoV-2 M\textsuperscript{pro}

SARS-CoV-2 belongs to the Betacoronavirus genus, which also includes SARS-CoV and MERS-CoV [16,24]. The RNA genome of SARS-CoV-2 comprises ~30,000 nucleotides with 14 open reading frames (ORFs). The replicase gene (ORF 1ab) occupies two-thirds of the genome [16,24]. To improve the efficiency of their own replication and transcription, a number of positive-sense, single-stranded RNA viruses encode large polyproteins, which are further hydrolyzed to produce essential subunits required for replication. The production of functional elements is an important regulatory mechanism for RNA viruses.

In the life cycle of SARS-CoV-2, ORF 1b encodes two long overlapping polyproteins, pp1a and pp1ab, which can be processed into 16 nonstructural proteins (nsp) required for RNA transcription and genome replication [16,25] (Fig. 1). This extensive proteolytic processing is achieved by two cysteine proteases, M\textsuperscript{pro} and papain-like protease (PL\textsuperscript{pro}). PL\textsuperscript{pro} is responsible for releasing nsp1-3 from the N-terminus of polyproteins. M\textsuperscript{pro} digests the polyprotein at the remaining 11 conserved cleavage sites (nsp 4/5, nsp5/nsp6, nsp6/nsp7, nsp7/nsp8, nsp8/nsp9, nsp9/nsp10, nsp10/nsp12, nsp12/nsp13, nsp13/nsp14, and nsp14/nsp 15), starting with the autolytic cleavage of this enzyme (nsp5) from the polyproteins pp1a and pp1ab. It is called the main protease because it plays a major role in processing replicate polyproteins and thus facilitates viral gene expression and replication. M\textsuperscript{pro} is a chymotrypsin-like cysteine protease (~33 kDa) [26]. Its alternative name is the 3C-like (3 C\textsuperscript{like}) protease, which was assigned based on the picornavirus 3C protease because of the similar substrate specificity and the identification of cysteine as a catalytic residue in the context of two β-barrel structures [27,28].

2.2. Overall structure of SARS-CoV-2 main protease

On February 5th, 2020, the first crystal structure of SARS-CoV-2 M\textsuperscript{pro} in complex with an inhibitor N3 ((Protein Data Bank (PDB) 6LU7) was released to the public shortly after the outbreak began [26]. To date, hundreds of structures for SARS-CoV-2 M\textsuperscript{pro} have been reported for drug development [29–33].

SARS-CoV-2 M\textsuperscript{pro} is composed of three domains [26] (Fig. 2A). Domain I (residues 8–101) and domain II (residues 102–184) contain antiparallel β-barrel structures, which are reminiscent of the chymotrypsin family. SARS-CoV-2 M\textsuperscript{pro} possesses a catalytic dyad (Cys-His), and the substrate-binding site is located in a cleft between domain I and domain II. Domain III (residues 201–306) contains five α-helices that arrange into a large antiparallel globular cluster. Domain III has a unique topology in CoVs, which is required for homodimer formation. Domain III is connected to domain II through a long loop (resides 185–200).

The crystal structures show that SARS-CoV-2 M\textsuperscript{pro} forms a homodimer with two protomers (denoted “A” and “B”) that are nearly perpendicular to each other, which is consistent with its active form in solution [34]. The dimer has a contact interface of ~1394 Å\textsuperscript{2}, predominantly between domain II of protomer A and the N-terminal residues of protomer B. In each protomer, the N-terminal finger (residues 1–7) inserts between domains II and III of its neighboring protomer, promoting the formation of the dimer and stabilizing the activity site of each protomer. Additionally, domain III regulates dimerization mainly through a salt-bridge interaction between Glu 290 of one protomer and Arg 4 from its neighbor [29].

![Fig. 1. The genomic organization of SARS-CoV-2. (A) The RNA genomic organization of SARS-CoV-2 (isolate Wuhan-Hu-1, NC_045,512). (B) Schematic representation of protease cleavage sites of the nonstructural protein (nsp) polyprotein. The orange arrows indicate papain-like protease (PL\textsuperscript{pro}) cleavage sites, and the tailless red arrows indicate the main protease (M\textsuperscript{pro}) cleavage sites. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)](image-url)
2.3. Substrate-binding pocket and catalytic site

The substrate-binding pocket of SARS-CoV-2 M\textsuperscript{pro} is located in a cleft between domain I and domain II. According to the nomenclature of substrates for proteases [35], with the cleavage site as the center, the positions for the residues from the cleavage site to the N-terminus are named P1, P2, P3, P4, and P5 ..., respectively. The positions for the residues from the cleavage site to the C-terminus are named P1', P2', P3', P4', and P5' ... respectively. The subsites in the substrate-binding pocket, which correspondingly accommodate each residue of the substrate, are named S1, S2, S3, S4, S5 ... and S1', S2', S3', S4', S5' ... . The CoV M\textsuperscript{pro}s are cysteine proteases, which are analogs of picornavirus 3C\textsuperscript{pro} proteases. Although their structural similarities are limited, the two classes of viral proteases share common features in the specificity for their substrates. It has been reported that SARS-CoV M\textsuperscript{pro} prefers Leu-Gln or Leu-Gly-Ala at the P2 site of SARS-CoV-2 M\textsuperscript{pro}. The side chain of the P3 subsite, which can accommodate the relatively bulky side chain of hydrophobic S4 subsite of SARS-CoV-2 M\textsuperscript{pro}, which suggests that only small amino acid residues such as Ala, Val, Thr, or Pro, could be held at the P4 position. The S1' of SARS-CoV-2 M\textsuperscript{pro} is a shallow subsite that can tolerate a small group of residues, such as Ser, Ala, or Asn.

3. Inhibitors of SARS-CoV-2 main protease

Previous studies indicate that M\textsuperscript{pro}s have a highly conserved substrate-binding pocket across species, which serves as a drug target for the design of broad-spectrum inhibitors [42,43]. The superposition of the crystal structures of CoV M\textsuperscript{pro}s, including those of SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-NL63, HCoV-229E, bat CoV-HKU4, mouse hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV), feline infectious peritonitis virus (FIPV), transmissible gastroenteritis virus (PDCoV), and infectious bronchitis virus (IBV) [26,29,39,42–52], shows that the most varied regions lie in the helical domain III and the surface loop (Fig. 2B). In contrast, the substrate-binding pocket is highly conserved among the M\textsuperscript{pro}s of all the CoVs listed above (Fig. 2C). This finding suggests that antiviral inhibitors targeting this pocket should have broad-spectrum activity against various CoVs.
In particular, SARS-CoV-2 and SARS-CoV share 96% sequence identity in their M<sub>pro</sub> sequences while their genomes only share approximately 82% identity. Among the 12 different residues between SARS-CoV-2 M<sub>pro</sub> and SARS-CoV M<sub>pro</sub>, only residue Ser 46 in SARS-CoV-2 M<sub>pro</sub> (Ala 46 in SARS-CoV M<sub>pro</sub>) is located close to the entrance of the catalytic pocket. Hence inhibitors that can effectively inhibit SARS-CoV M<sub>pro</sub> are expected to have a similar effect on SARS-CoV-2 M<sub>pro</sub>. In the last few months, a series of inhibitors has been identified for SARS-CoV-2 M<sub>pro</sub> (Fig. 3), and the structures of M<sub>pro</sub> complexes have already been determined.

3.1. Peptidomimetic inhibitor with a Michael acceptor

Compound 1 (N3) is the first inhibitor whose structure in complex with SARS-CoV-2 M<sub>pro</sub> has been deposited to the PDB [26]. This peptidomimetic inhibitor contains a Michael acceptor as a warhead that can irreversibly modify the catalytic residue Cys145. The strategy of designing this inhibitor involves replacing the amide bond at the cleavage site of the substrate with a Michael acceptor. The cysteine residue and the Michael acceptor group (warhead) of the inhibitor undergo 1,4-addition. In this process, the protonation of the α-carbanion from catalytic His-H<sup>+</sup> results in the covalent bond formation. The structure shows that replacing the glutamine which is absolutely required at the P1 site, with a lactam group can result in strong binding for the inhibitor at the S1 subsite. Compound 1 inhibited SARS-CoV-2 with a half-maximal effective concentration (EC50) value of 16.77 μM in a plaque-reduction assay.

3.2. Peptidomimetic α-ketoamide inhibitors

Zhang et al. recently reported three α-ketoamides, including compound 2 (11r), 3 (13a), and 4 (13b), which can strongly inhibit
SARS-CoV-2 M<sup>P50</sup> [29]. Inhibitory activity assays and the crystal structure of compound 4 complexed with SARS-CoV-2 M<sup>P50</sup> revealed that replacing the P2–P3 amide bond with a pyridone ring could improve the compound half-life in plasma. Additionally, compared with that of enterovirus 3C proteases, the S2 binding pocket of M<sup>P50</sup> is smaller and less flexible.

α-Ketoamide is commonly used as a viral serine protease warhead in approved hepatitis C virus (HCV) drugs, such as boceprevir. Recently, researchers showed that compound 5 (boceprevir) and compound 6 (GC376), an inhibitor in preclinical studies against FIPV, could efficaciously inhibit SARS-CoV-2 in Vero cells by targeting M<sup>P50</sup> [32,53,54].

3.3. Peptidomimetic inhibitor with an aldehyde

Compound 7 (11a) and 8 (11b) exhibited potent inhibition of SARS-CoV-2 M<sup>P50</sup> with half-maximal inhibitory concentration (IC<sub>50</sub>) values of 0.053 μM and 0.040 μM, respectively [30]. Dai et al. designed these two peptidomimetic aldehydes with an indole moiety at the N-terminus (P3 site) and a C-terminal aldehyde warhead. The crystal structures show that these compounds can covalently bind to the catalytic site Cys145. Additionally, both peptidomimetic aldehyde compounds exhibited potent anti-SARS-CoV-2 infection activity in Vero cell-based assays and good pharmacokinetic and toxicity properties.

3.4. Inhibitors from drug repurposing

The repurposing of approved pharmaceutical drugs and drug candidates provides an alternative approach that allows the rapid identification of potential drug leads to addressing the current COVID-19 pandemic crisis. Jin et al. identified six hits, including ebselen (compound 9), disulfram (compound 10), carmofur (compound 11), shikonin (compound 12), tigeldusib (compound 13), and PX-12 (compound 14), via high-throughput screening (HTS). An in vitro enzymatic assay showed that the IC<sub>50</sub> values of the six compounds ranged from 0.67 to 21.4 μM [26].

Among them, ebselen (9) exhibited promising antiviral activity in a plaque-reduction assay (EC<sub>50</sub> = 4.67 μM). Ebselen (9) is an organoselenium compound that has previously been investigated for the treatment of multiple diseases, including bipolar disorders [55] and hearing loss [56]. Its low cytotoxicity in humans has been evaluated in clinical trials [55–57]. Ebselen (9) has been approved by the U.S. Food and Drug Administration (FDA) to enter phase II clinical trials (NCT04484025 and NCT04483973) to treat COVID-19. Carmofur (11) is a derivative of 5-fluorouracil (5-FU) and an approved antineoplastic agent. The X-ray crystal structure of SARS-CoV-2 M<sup>P50</sup> in complex with carmofur (11) reveals that the carbonyl reactive group of carmofur (11) is covalently bound to the catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 site [31]. Carmofur (11) inhibits viral replication in cells (EC<sub>50</sub> = 24.30 μM) and provides a basis for the rational design of analogs with enhanced inhibitory efficacy to treat COVID-19.

Virtual screening identified cinanserin (compound 15) as an inhibitor targeting SARS-CoV-2 M<sup>P50</sup>. It is a well-characterized se-rotonin and a potential inhibitor [26]. It has previously been shown to inhibit SARS-CoV M<sup>P50</sup> with an IC<sub>50</sub> value of 5 μM [58]. It has displayed anti-SARS-CoV-2 activity with an EC<sub>50</sub> value of 20.6 μM, which potential for further optimization as an antiviral drug lead.

Su et al. recently reported that baicalin (compound 16) and baicaeolin (compound 17), two natural products from Scutellaria baicalensis, are novel noncovalent, nonpeptidomimetic inhibitors for SARS-CoV-2 M<sup>P50</sup> (IC<sub>50</sub> = 6.41 μM and IC<sub>50</sub> = 0.94 μM, respectively) [33]. Both baicalin (16) and baicaeolin (17) showed dose-dependent inhibition of SARS-CoV-2 replication, with EC<sub>50</sub> values of 27.87 μM and 2.94 μM, respectively. The crystal structure of SARS-CoV-2 M<sup>P50</sup> in complex with baicalin (17) revealed that this inhibitor noncovalently binds to the substrate-binding pocket of M<sup>P50</sup> through interacting with the catalytic dyad His41-Cys145, the crucial S1/S2 subsites, and the oxyanion loop. It may act as a “shield” to effectively prevent the substrate from accessing the catalytic dyad [33].

By virtual screening of a U.S. FDA-approved drug library, Liu et al. identified an anticoagulation agent dipryridamole (compound 18), which may bind to SARS-CoV-2 M<sup>P50</sup> through hydrogen bonds and hydrophobic interactions. It also showed an inhibitory effect by an in vitro assay (IC<sub>50</sub> = 0.53 μM) [59]. Furthermore, it has been reported that dipryridamole (18) showed therapeutic improvement against COVID-19 in a small-scale clinical trial [59].

3.5. Fragment screening of inhibitors

To accelerate the development of antiviral drugs against COVID-19, Douangamath et al. performed large-scale fragment screening by combining mass spectrometry and X-ray approaches against SARS-CoV-2 M<sup>P50</sup> [60]. The crystallographic screen identified 71 hits that bind to the substrate-binding pocket and 3 hits near the dimer interface. These structures provide information to develop more effective inhibitors against SARS-CoV-2 M<sup>P50</sup>.

4. SARS-CoV-2 RdRP

4.1. Overview of SARS-CoV-2 RdRP

After entry into the cells, SARS-CoV-2 employs a multisubunit replication and transcription complex (RTC) to accomplish the replication and transcription of its RNA genome [61]. The RTC is assembled by an array of nsps released from polyprotein pp1ab by viral protease cleavage [62]. In this multisubunit machinery, the core component is nsp12, which is the catalytic subunit and is also called RdRP. Nsp12 is responsible for the catalysis of elongation of a new RNA chain from RNA templates [63]. However, nsp12 itself displays only little activity in RNA synthesis, and two other accessory factors, nsp7 and nsp8, are required to increase nsp12 binding to the template and subsequent RNA synthesis [64,65].

The RdRP core consists of the thumb, palm, and fingers subdomains forming an encircled human right-hand architecture, which is involved in template binding, polymerization, nucleoside triphosphate (NTP) entry, and other related functions [66,67]. In addition, SARS-CoV-2 nsp12 contains a nidovirus-specific N-terminal RdRP-associated nucleotidyltransferase (NiRAN) domain revealed by cryo-electron microscopy (cryo-EM) structures. The RdRP domain and NiRAN domain are bridged by an interface domain [67,68]. RdRP is an attractive antiviral drug target because of its essential role in the viral life cycle. Multiple nucleotide and nucleoside analogs targeting viral RdRP have been in clinical trials for the treatment of COVID-19 [69–71], such as remdesivir (RDV) and favipiravir. In comparison with other viral RdRPs, SARS-CoV-2 nsp12 shows structural similarity. Multiple key amino acid residues at the active site are conserved [72], indicating that antivirals targeting RdRPs may provide the first lines of defense against future CoV-associated diseases.

4.2. Structures of the SARS-CoV-2 RdRP complex

A series of cryo-EM structures has recently revealed that SARS-CoV-2 nsp12 (RdRP) forms a complex with nsp7 and nsp8, as previously observed for the RdRP complex from SARS-CoV. The viral RdRP interacts with an nsp7–nsp8 pair through its thumb subdomain and with another molecule of nsp8 through its finger
subdomain \([66–68,72–75]\). These structures show that although the SARS-CoV-2 polymerase shares a similar structural architecture with that of SARS-CoV, an N-terminal \(\beta\) hairpin of SARS-CoV-2 nsp12 inserts into the groove clamped by the NiRAN domain and the palm subdomain, resulting in a cluster of tight contacts to stabilize the overall complex (Fig. 4B). The most significant hit for the NiRAN domain identified by the DALI webserver search is \(P.\ syringae\) SelO \([74]\), a pseudokinase harboring a kinase fold without key catalytic residues for canonical kinases \([76]\). Interestingly, the structural analysis shows that the residues involved in ADP-Mg\(^{2+}\) binding at the N-terminal domain of SARS-CoV nsp12 are very similar to those involved in AMP-PNP binding in SelO \([74]\). Although whether the NiRAN domain possesses nucleotidylation activity has yet to be determined, it has been found that the NiRAN domain plays an essential role in viral replication for SARS-CoV \([77]\), suggesting that it may serve as a new druggable site.

The structures of nsp12 in complex with nsp7, nsp8, and RNA template–product duplex provide detailed information for the interactions between RdRP and RNA. The cryo-EM structure of the RdRP complex shows that RdRP engages with over two turns of duplex RNA and identifies a long protruding RNA and extended protein regions in nsp8 \([73]\). The active site cleft of nsp12 binds to the first turn of RNA, and two copies of nsp8 bind to opposite sides of the cleft and the second turn of RNA (Fig. 4C).

It has been proposed that RdRP is able to cooperate with other nsp proteins for viral genomic replication and transcription. SARS-CoV-2 nsp13 belongs to a superfamily of 1B helicases that unwind RNA in an NTP-dependent manner \([78–80]\). Another cryo-EM structure of the RdRP complex demonstrates that nsp12, nsp8, nsp7, and nsp13 are able to form a larger complex \([74]\). This complex contains two molecules of nsp13, each of which binds to the N-terminal extension of each copy of nsp8. One nsp13 molecule also contacts the thumb subdomain of nsp12 (Fig. 4F). A possible backtracking mechanism was proposed for the subgenomic RNA transcription.

5. Inhibitors targeting SARS-CoV-2 RdRP

RDV, a nucleotide analog inhibitor that was developed targeting RdRP from Ebola virus, has demonstrated broad-spectrum inhibitory effects against a wide range of RNA viruses, including filoviruses, arenaviruses, and CoVs \([81–83]\). RDV is a prodrug that can be metabolized into its active triphosphate form in the cells (Fig. 4E), which could interfere with viral RNA synthesis and inhibit the

![Fig. 4. Structures of SARS-CoV-2 RdRP complex.](image-url)
elaboration of the viral RNA product [81]. During the COVID-19 pandemic, clinical trials for RDV have been accelerated to determine its safety and efficacy in several countries. The structure of SARS-CoV-2 RdRP-RNA in complex with a monophosphate form of remdesivir (RDV-MP) reveals that incorporation of the active form of RDV may result in a stalled pre-translocated catalytic state (Fig. 4D), suggesting a delayed-chain-termination mechanism [72,84]. When RdRP synthesis proceeds to the i+3 position (where i corresponds to the position of the first incorporated RDV-MP), the first incorporated RDV-MP will be at position –3 or –4 for the pre- or post-translocated state, respectively. Nevertheless, the 1’-CN substituent of incorporated RDV-MP could encounter a steric clash with a serine side chain and probably lead to destabilization of the complex, hampering subsequent translocation. These structures provide a basis to develop antiviral drugs that interfere with this pivotal process of viral replication and transcription.

6. Concluding remarks

Following SARS-CoV and MERS-CoV, which emerged in 2003 and 2012, respectively, SARS-CoV-2 is the third CoV that crossed the species barrier to cause severe diseases in humans. Hence CoVs may still pose a threat to human health in the future. It is a plausible strategy to develop broad-spectrum antivirals as the first-line defense for future CoV-associated diseases. In the life cycle of CoVs, the Mpro and RdRP are prime drug targets that are well conserved among different CoVs. Great effort has been devoted to structural and functional studies of Mpro and RdRP, which can promote drug development against COVID-19 and other CoV-associated diseases.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

1. National Natural Science Foundation of China, China, 81520108019, 813300237;
2. Science and Technology Commission of Shanghai Municipality, China, 20431900200;
3. Natural Science Foundation of Tianjin, China, 18JCQJC48000.

References

[1] A.M.Q. King, M.J. Adams, E. Lefkowitz, E.B. Carstens. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses, Elsevier Science, 2011.
[2] E. de Wit, N. van Doremalen, D. Falzarano, V.J. Munster, SARS and MERS: the emergence of coronaviruses as human pathogens. J Gen Virol 92 (2011) 2373–2384. https://doi.org/10.1099/vir.0.034188-0.
[3] Y. Fan, K. Zhao, Z.-L. Shi, P. Zhou, Bat coronaviruses in China, Viruses 11 (2019) 1353.
[4] P.C. Woo, S.K. Lau, Y. Hung, K.-Y. Yuen, Coronavirus diversity, phylology and interspecies jumping, Exp. Biol. Med. 234 (2009) 1117–1127.
[5] K. Jung, I.L. Sael, Porcine epidemic diarrhoea virus infection: etiology, epidemiology, pathogenesis and immunopathology, Rev. Sci. Tech. 20 (2001) 134–143. https://doi.org/10.20588/rst.20.2001.134.143.
[6] N.C. Pedersen, A review of feline infectious peritonitis virus infection, J Feline Med Surg. 11 (2009) 225–258. https://doi.org/10.1177/1098615X09354132.
[7] K. Jung, H. Lu, I.L. Sael, Porcine deltacoronavirus infection: etiology, cell culture and pathogenesis, Journal of virology and virology. J Virol. 90 (2016) 50–56.
[8] C.J. Paules, H.D. Marston, A.S. Fauci, Coronavirus infections—more than just the common cold, J. Am. Med. Assoc. 233 (2000) 707–708. https://doi.org/10.1001/jama.2000.0757.
[9] T.S. Fung, D.X. Liu, Human coronavirus: host-pathogen interaction, Annu. Rev. Microbiol. 73 (2019) 529–557.
[10] N. Zhong, B. Zheng, Y. Li, L. Poon, Z. Xie, K. Chan, P. Li, S. Tan, Q. Chang, J. Xie, Epidemiology and cause of severe acute respiratory syndrome (SARS) in

Guangdong, People's Republic of China, in February, 2003, Lancet 362 (2003) 1353–1358.
[11] WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/index.html, 2003.
[12] A.M. Zaki, V. van Boheemen, T.M. Bestebroer, A.D. Osterhaus, R.A. Fouchier. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N Engl. J Med. 367 (2012) 1814–1820.
[13] WHO. Middle East respiratory syndrome coronavirus. https://www.who.int/emergencies/mers-cov/en/, 2019.
[14] Z. Jin, H. Wang, Y. Duan et al. Biochemical and Biophysical Research Communications 538 (2021) 63–71.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

1. National Natural Science Foundation of China, China, 81520108019, 813300237;
2. Science and Technology Commission of Shanghai Municipality, China, 20431900200;
3. Natural Science Foundation of Tianjin, China, 18JCQJC48000.

References

[1] A.M.Q. King, M.J. Adams, E. Lefkowitz, E.B. Carstens. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses, Elsevier Science, 2011.
[2] E. de Wit, N. van Doremalen, D. Falzarano, V.J. Munster, SARS and MERS: the emergence of coronaviruses as human pathogens. J Gen Virol 92 (2011) 2373–2384. https://doi.org/10.1099/vir.0.034188-0.
[3] Y. Fan, K. Zhao, Z.-L. Shi, P. Zhou, Bat coronaviruses in China, Viruses 11 (2019) 1353.
[4] P.C. Woo, S.K. Lau, Y. Hung, K.-Y. Yuen, Coronavirus diversity, phylology and interspecies jumping, Exp. Biol. Med. 234 (2009) 1117–1127.
[5] K. Jung, I.L. Sael, Porcine epidemic diarrhoea virus infection: etiology, epidemiology, pathogenesis and immunopathology, Rev. Sci. Tech. 20 (2001) 134–143. https://doi.org/10.20588/rst.20.2001.134.143.
[6] N.C. Pedersen, A review of feline infectious peritonitis virus infection, J Feline Med Surg. 11 (2009) 225–258. https://doi.org/10.1177/1098615X09354132.
[7] K. Jung, H. Lu, I.L. Sael, Porcine deltacoronavirus infection: etiology, cell culture and pathogenesis, Journal of virology and virology. J Virol. 90 (2016) 50–56.
[8] C.J. Paules, H.D. Marston, A.S. Fauci, Coronavirus infections—more than just the common cold, J. Am. Med. Assoc. 233 (2000) 707–708. https://doi.org/10.1001/jama.2000.0757.
[9] T.S. Fung, D.X. Liu, Human coronavirus: host-pathogen interaction, Annu. Rev. Microbiol. 73 (2019) 529–557.
[10] N. Zhong, B. Zheng, Y. Li, L. Poon, Z. Xie, K. Chan, P. Li, S. Tan, Q. Chang, J. Xie, Epidemiology and cause of severe acute respiratory syndrome (SARS) in
J. Chen, B. Malone, E. Llewellyn, M. Grasso, P.M.M. Shelton, P.D.B. Olinares, K. Maruthi, E.T. Eng, H. Vatandaslar, B.T. Chait, T.M. Kapoor, S.A. Darst, E.A. Campbell, Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex, Cell 182 (2020) 1560–1573, https://doi.org/10.1016/j.cell.2020.07.033, e1513.

Q. Peng, R. Peng, B. Yuan, J. Zhao, M. Wang, X. Wang, Q. Wang, Y. Sun, Z. Fan, J. Qi, G.F. Gao, Y. Shi, Structural and biochemical characterization of the nsp12-nsp8 core polymerase complex from SARS-CoV-2, Cell Rep. 31 (2020) 107774, https://doi.org/10.1016/j.celrep.2020.107774.

M. Dudkiewicz, T. Szczepinska, M. Grymberg, K. Pawlowski, A novel protein kinase-like domain in a selenoprotein, widespread in the tree of life, PloS One 7 (2012), e32138, https://doi.org/10.1371/journal.pone.0032138.

K.C. Lehmann, A. Gulyaeva, J.C. Zevenhoven-Dobbe, G.M. Janssen, M. Ruben, H.S. Overkleeft, P.A. van Veelen, D.V. Samborskiy, A.A. Kravchenko, A.M. Leontovich, I.A. Sidorov, E.J. Snijder, C.C. Posthuma, A.E. Gorbalenya, Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses, Nucleic Acids Res. 43 (2015) 8416–8434, https://doi.org/10.1093/nar/gkv838.

N.R. Lee, H.M. Kwon, K. Park, S. Oh, Y.J. Jeong, D.E. Kim, Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsp13, Nucleic Acids Res. 38 (2010) 7626–7636, https://doi.org/10.1093/nar/gkp647.

J.A. Tanner, R.M. Watt, Y.B. Chai, L.Y. Lu, M.C. Lin, J.S. Peiris, L.L. Poon, H.F. Kung, J.D. Huang, The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5′ to 3′ viral helicases, J. Biol. Chem. 278 (2003) 39578–39582, https://doi.org/10.1074/jbc.C300328200.

R. Zhang, Y. Li, T.J. Cowley, A.D. Steinbrenner, J.M. Phillips, B.L. Yount, R.S. Baric, S.R. Weiss, The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM-Wu, J. Virol. 89 (2015) 3598–3609, https://doi.org/10.1128/jvi.03525-14.

T.K. Warren, R. Jordan, M.K. Lo, A.S. Ray, R.L. Mackman, V. Soloveva, D. Siegel, M. Perron, R. Bannister, H.C. Hui, N. Larson, R. Strickley, J. Wells, K.S. Stuthman, S.A. Van Tongeren, N.L. Garza, G. Donnelly, A.C. Shurtleff, C.J. Retterer, D. Gharabe, R. Zamani, T. Kenny, B.P. Eaton, E. Grimes, L.S. Welch, L. Gomba, C.L. Wilhelmson, D.K. Nichols, J.E. Nuss, E.R. Nagle, J.R. Kugelman, G. Palacios, E. Doerrf, S. Neville, E. Carra, M.O. Clarke, Z. Zhang, W. Lew, B. Ross, Q. Wang, K. Chun, L. Wolfe, D. Babusis, Y. Park, K.M. Stray, I. Trancheva, J.Y. Feng, O. Barauskas, Y. Xu, P. Wong, M.R. Braun, M. Flint, L.K. McMullan, S.S. Chen, R. Fearis, S. Swaminathan, D.L. Mayers, C.F. Spiropoulou, W.A. Lee, S.T. Nichol, T. Cihlar, S. Bavari, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature 531 (2016) 381–385, https://doi.org/10.1038/nature17180.

E. de Wit, F. Feldmann, J. Cronin, R. Jordan, A. Okumura, T. Cihlar, S. Thomas, D. Scott, T. Cihlar, H. Feldmann, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 6771–6776, https://doi.org/10.1073/pnas.1922083117.

M.K. Lo, R. Jordan, A. Arvey, J. Sudhamsu, P. Shrivastava-Ranjan, A.L. Hotard, M. Flint, L.K. McMullan, D. Siegel, M.O. Clarke, R.L. Mackman, H.C. Hui, M. Perron, A.S. Ray, T. Cihlar, S.T. Nichol, C.F. Spiropoulou, GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses, Sci. Rep. 7 (2017) 43395, https://doi.org/10.1038/srep43395.

C.J. Gordon, E.P. Tchesnokov, E. Woolner, J.K. Perry, J.Y. Feng, D.P. Porter, M. Gottle, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J. Biol. Chem. 295 (2020) 6785–6797, https://doi.org/10.1074/jbc.A120.013679.